Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
48
ZVRA Quote, Financials, Valuation and Earnings
Last price:
$8.58
Seasonality move
:
-0.81%
Day range:
$8.42 - $8.65
52-week range:
$4.20 - $9.76
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.93x
P/B ratio:
6.57x
Volume:
138.5K
Avg. volume:
629.3K
1-year change:
72.84%
Market cap:
$458.5M
Revenue:
$27.5M
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingZevra Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Zevra Therapeutics has an estimated upside of 132.83% from its current price of $8.59.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $8.59.
Fair Value
-
According to the consensus of 3 analysts, Zevra Therapeutics has 132.83% upside to fair value with a price target of -- per share.
ZVRA vs. S&P 500
-
Over the past 5 trading days, Zevra Therapeutics has underperformed the S&P 500 by -1.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Zevra Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Zevra Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Zevra Therapeutics reported revenues of $3.7M.
Earnings Growth
-
Zevra Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Zevra Therapeutics reported earnings per share of -$0.69.
Enterprise value:
428M
EV / Invested capital:
3.33x
Price / LTM sales:
14.93x
EV / EBIT:
--
EV / Revenue:
17.48x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-6.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$16.4M
Return On Assets:
-56.14%
Net Income Margin (TTM):
-366.14%
Return On Equity:
-159.89%
Return On Invested Capital:
-85.03%
Operating Margin:
-739%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $10.7M | $16.6M | $24.5M | $2.9M | $3.7M | |
| Gross Profit | $10.5M | $15.6M | $16.4M | $2.8M | $1.4M | |
| Operating Income | -$36.1M | -$43.8M | -$86.7M | -$15.4M | -$27.3M | |
| EBITDA | -$35.1M | -$18.3M | -$78.2M | -$9.8M | -$29.3M | |
| Diluted EPS | -$0.89 | -$0.60 | -$2.11 | -$0.30 | -$0.69 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $8.1M | $134.6M | $85.1M | $137M | $99.4M | |
| Total Assets | $11.2M | $137.2M | $119.6M | $139M | $191.6M | |
| Current Liabilities | $70.8M | $3.7M | $8.4M | $21.7M | $34.5M | |
| Total Liabilities | $73.5M | $5.4M | $25.8M | $71.5M | $121.8M | |
| Total Equity | -$62.3M | $131.7M | $93.8M | $67.5M | $69.8M | |
| Total Debt | $66.7M | -- | $12.8M | $43.9M | $58.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$15.1M | -$21.8M | -$69.6M | -$4.6M | -$18.1M | |
| Cash From Investing | -$52.1M | -$28M | -$6.1M | -$44.5M | -$31.4M | |
| Cash From Financing | $5.7M | $23.2M | $86.3M | $26.3M | $64.8M | |
| Free Cash Flow | -$15.2M | -$22.1M | -$69.6M | -$4.8M | -$18.1M | |
ZVRA
Sector
Market Cap
$458.5M
$46.1M
Price % of 52-Week High
88.01%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
-21.97%
-0.6%
1-Year Price Total Return
72.84%
-30.52%
Beta (5-Year)
1.972
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$8.49
200-day SMA
Buy
Level
$6.61
Bollinger Bands (100)
Buy
Level
7.31 - 8.85
Chaikin Money Flow
Sell
Level
-112.3M
20-day SMA
Sell
Level
$8.88
Relative Strength Index (RSI14)
Sell
Level
46.60
ADX Line
Sell
Level
17.77
Williams %R
Neutral
Level
-64.4068
50-day SMA
Sell
Level
$8.71
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
45M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.3718)
Sell
CA Score
(Annual)
Level (-1.8963)
Sell
Beneish M-Score
(Annual)
Level (29.1548)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (3.4804)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Stock Forecast FAQ
In the current month, ZVRA has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ZVRA average analyst price target in the past 3 months is --.
-
Where Will Zevra Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Zevra Therapeutics share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Zevra Therapeutics?
Analysts are divided on their view about Zevra Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Zevra Therapeutics is a Sell and believe this share price will drop from its current level to --.
-
What Is Zevra Therapeutics's Price Target?
The price target for Zevra Therapeutics over the next 1-year time period is forecast to be -- according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ZVRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Zevra Therapeutics is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ZVRA?
You can purchase shares of Zevra Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Zevra Therapeutics shares.
-
What Is The Zevra Therapeutics Share Price Today?
Zevra Therapeutics was last trading at $8.58 per share. This represents the most recent stock quote for Zevra Therapeutics. Yesterday, Zevra Therapeutics closed at $8.59 per share.
-
How To Buy Zevra Therapeutics Stock Online?
In order to purchase Zevra Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 26
Power Solutions International [PSIX] is up 6.55% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 1.98% over the past day.
Buy
75
SMLR alert for Dec 26
Semler Scientific [SMLR] is down 3.2% over the past day.
